Navigation Links
Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
Date:11/11/2009

BROOMFIELD, Colo., Nov. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today that it will present at Lazard Capital Markets 6th Annual Healthcare Conference November 17-18, 2009 at the St. Regis Hotel in New York.

Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona(TM) on Tuesday, November 17 at 4:10 p.m. EST. A breakout session will follow Dr. Orndorff's presentation where he will be available for questions and answers.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.

Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. Accera engages in research, development and commercialization of other clinical applications for Axona, and has a wholly owned subsidiary, Neuera Pharmaceuticals, with a pipeline of small molecule drugs for neurodegenerative diseases.

For more information about Accera, please visit www.accerapharma.com.

    Contacts:
    Accera, Inc.
    Steve Orndorff, Ph.D.
    President and CEO
    sorndorff@accerapharma.com

    Tiberend Strategic Advisors, Inc.
    (212) 827-0020
    Andrew Mielach
    amielach@tiberendstrategicadvisors.com

    or

    Farrell Denby
    fdenby@tiberendstrategicadvisors.com

SOURCE Accera, Inc.


'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
2. CryoLife to Present at Upcoming Investor Conferences in New York
3. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
4. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
5. MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
6. VIVUS to Present at Lazard Capital Markets Healthcare Conference
7. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
8. Thoratec Presentation at Canaccord Adams Conference to be Webcast
9. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
10. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
11. Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ReNeuron reported in December 2016 positive Phase II trial ... not meeting the three-month time frame of a two-point improvement ... (ARAT). As a result, the company has confirmed that it ... Beyond CTX, we expect safety and efficacy data from its ... from its critical limb ischaemia (CLI) trial. Our rNPV has ...
(Date:3/23/2017)... , Mar 23, 2017 The Board ... to the Annual General Meeting, which is to take place on ... 2 in Lund, Sweden . ... Please see the attached notification, which ... Inrikes Tidningar. NeuroVive Pharmaceutical AB (Publ) The Board Of ...
(Date:3/22/2017)... Corp. (NASDAQ: DRIO), a leading global digital health ... today reported financial and operational results for the ... 2016. 2016 Highlights ... to the full year 2015  ... Direct-to-consumer model launched in U.S. ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... ... prominently feature 150+ Hospital and Health System Executive Speakers including: , , ... President of the United States of America: George W. Bush , Boxing Legend, ... Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance and Utilization ... ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , It is ... the association, but also to the Health Care Quality and Patient Safety movements. Diplomates ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 — ... the new EU MDR language change the way manufacturers approach CERs? , ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life ... is the creation of published author Bonetta Rose, a wife, mother and grandmother committed ... Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events in the ...
Breaking Medicine News(10 mins):